Renaissance Technologies LLC Has $2.87 Million Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Renaissance Technologies LLC lifted its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 77.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 166,200 shares of the company's stock after acquiring an additional 72,400 shares during the quarter. Renaissance Technologies LLC owned approximately 0.44% of Entrada Therapeutics worth $2,874,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Geode Capital Management LLC boosted its position in Entrada Therapeutics by 8.8% during the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock worth $9,214,000 after purchasing an additional 46,512 shares during the period. Barclays PLC boosted its holdings in shares of Entrada Therapeutics by 210.6% during the 3rd quarter. Barclays PLC now owns 45,110 shares of the company's stock worth $720,000 after buying an additional 30,585 shares during the period. State Street Corp grew its stake in Entrada Therapeutics by 5.5% in the 3rd quarter. State Street Corp now owns 469,601 shares of the company's stock valued at $7,504,000 after buying an additional 24,385 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Entrada Therapeutics during the fourth quarter worth approximately $36,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Entrada Therapeutics by 44.0% during the fourth quarter. SG Americas Securities LLC now owns 14,036 shares of the company's stock worth $243,000 after acquiring an additional 4,291 shares during the period. 86.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Monday, March 31st.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA traded up $0.19 during midday trading on Wednesday, reaching $9.13. The company's stock had a trading volume of 127,276 shares, compared to its average volume of 126,255. The company has a market cap of $343.24 million, a P/E ratio of 5.74 and a beta of 0.04. Entrada Therapeutics, Inc. has a fifty-two week low of $7.10 and a fifty-two week high of $21.79. The business's 50 day moving average price is $9.69 and its two-hundred day moving average price is $14.21.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.69. The company had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. Sell-side analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.